SCHEMBL3734735

SCHEMBL3734735

COc1ncc(-c2ccccc2N2CCN(C(=O)CN3C(=O)c4ccccc4S3(=O)=O)CC2)cn1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.64
MAPK1 P28482 1/20 0.64
SMN1; SMN2 Q16637 3/20 0.60
RAB9A P51151 6/20 0.56
NPC1 O15118 5/20 0.56
TSHR P16473 1/20 0.54
MAPT P10636 3/20 0.51
PKM P14618 1/20 0.51
CYP2C19 P33261 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
TP53 P04637 1/20 0.49
HSP90AA1 P07900 1/20 0.49
PAX8 Q06710 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
ATM Q13315 1/20 0.49
HTT P42858 1/20 0.48
DRD2 P14416 2/20 0.48
DRD4 P21917 1/20 0.48
DRD5 P21918 1/20 0.48
DRD3 P35462 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL162487 0.81 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2RAB9ANPC1TSHR
SCHEMBL3735656 0.80 MAPT (0.47) MAPK1SMN1; SMN2RAB9ATSHRMAPT
SCHEMBL3735537 0.78 GAA (0.57) ALDH1A1SMN1; SMN2RAB9ANPC1TSHR
SCHEMBL3724570 0.77 GAA (0.53) ALDH1A1SMN1; SMN2RAB9AMAPTCYP2C19
SCHEMBL113988 0.77 MAPT (0.46) ALDH1A1MAPK1SMN1; SMN2TSHRMAPT
SCHEMBL112660 0.77 LMNA (0.53) ALDH1A1SMN1; SMN2MAPTTP53L3MBTL1
SCHEMBL3732667 0.77 CXCR3 (0.47) ALDH1A1SMN1; SMN2TSHRMAPTTP53
SCHEMBL3735389 0.76 L3MBTL1 (0.45) MAPK1SMN1; SMN2TSHRMAPTL3MBTL1
SCHEMBL113467 0.76 CXCR3 (0.53) SMN1; SMN2TSHRMAPTTP53
SCHEMBL115433 0.76 MAPT (0.47) ALDH1A1SMN1; SMN2TSHRMAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8450317-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-28 US claimed
EP-2424840-B1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2014-08-06 EP disclosed
US-8450317-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-28 US disclosed
US-8450317-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-28 US disclosed
US-8450317-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-28 US disclosed
US-20100280028-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 US disclosed
US-20100280028-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 US disclosed
US-20100280028-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280028-A1 CXCR3 RECEPTOR ANTAGONISTS CXCR3, CXCR1, CXCR2 ALDH1A1 1298/4885MAPK1 1967/4885SMN1; SMN2 4646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.